Barrett's esophagus is a metaplastic condition that develops in an estimated 10-20% of persons with long-standing gastroesophageal reflux disease (GERD). Patients with this condition are at high risk, estimated at 1-2% per year, of developing esophageal adenocarcinoma, a rapidly fatal cancer that, for unknown reasons, has risen sharply in incidence since the mid-1970s. Although much research has been directed toward identifying predictors of progression i patients with Barrett's esophagus, there is little information about the causes of the conditions itself. The first Specific Aim of this case-control study is to compare cases with newly diagnosed Barrett's esophagus (N=335) to controls from the general population (N=335) to test the hypothesis that specific environmental exposures and host factors increase risk of Barrett's metaplasia, and to estimate the fraction of cases attributable to them. Also to be examined will be the role of obesity, diet high in fat and low in fruits and vegetables, low serum vitamin C, vitamin E, carotenoids and selenium, tobacco use, alcohol consumption, use of medications that promote reflux and family history. The second Specific Aim is to identify determinant of Barrett's esophagus among individuals with severe and persistent GERD, by comparing cases to patients undergoing upper endoscopy for reflux symptoms, but who are biopsy-proven negative for Barrett's esophagus (N=335). Specifically, the hypothesis to be tested is that among patients with GERD: 1) cigarette smoking, alcohol consumption and dietary intake of nitrosamines are associated with increased risk of Barrett's esophagus, and that higher dietary intake and serum levels of antioxidants are associated with decreased risk; and 2) duodenogastric reflux (measured as the concentration of bile in fasting gastric juice) is associated with an increased risk of metaplasia. The prevalence of short-segment Barrett's will be estimated among patients undergoing endoscopy for GERD, using the largest sample of endoscoped patients, to date, all biopsied according to a standard protocol. Given that 95% of persons with Barrett's esophagus remain undiagnosed and that esophageal adenocarcinoma survival rates are dismal, the most direct means of reducing esophageal adenocarcinoma incidence amy be by preventing metaplasia, rather than by the surveillance and treatment of patients already diagnosed with the condition.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA072866-03
Application #
2895782
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Patel, Appasaheb1 R
Project Start
1997-09-05
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dong, Jing; Levine, David M; Buas, Matthew F et al. (2018) Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol 16:1598-1606.e4
Dong, Jing; Buas, Matthew F; Gharahkhani, Puya et al. (2018) Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology 154:1273-1281.e3
Buas, Matthew F; He, Qianchuan; Johnson, Lisa G et al. (2017) Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 66:1739-1747
Buas, Matthew F; Gu, Haiwei; Djukovic, Danijel et al. (2017) Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics 13:
Li, Nan; Petrick, Jessica Leigh; Steck, Susan Elizabeth et al. (2017) Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis. Eur J Epidemiol 32:1007-1017
Thrift, Aaron P; Vaughan, Thomas L; Anderson, Lesley A et al. (2017) External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol 15:1124-1126
Ek, Weronica E; Lagergren, Katarina; Cook, Michael et al. (2016) Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer 138:1146-52
Gharahkhani, Puya; Fitzgerald, Rebecca C; Vaughan, Thomas L et al. (2016) Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol 17:1363-1373
Dai, James Y; Tapsoba, Jean de Dieu; Buas, Matthew F et al. (2016) Constrained Score Statistics Identify Genetic Variants Interacting with Multiple Risk Factors in Barrett's Esophagus. Am J Hum Genet 99:352-65
Thrift, Aaron P; Anderson, Lesley A; Murray, Liam J et al. (2016) Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol 111:1528-1535

Showing the most recent 10 out of 31 publications